To determine the clinical efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) in the treatment of uncomplicated falciparum malaria in children living in north-western Tanzania and in western Kenya. during 42 day follow-up [clinicaltrials_resource:d63d0cc507440c59c222ee52b33593ce]
Artemether-lumefantrine; currently the first line treatment in Tanzania
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To determine the clinical efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) in the treatment of uncomplicated falciparum malaria in children living in north-western Tanzania and in western Kenya. during 42 day follow-up [clinicaltrials_resource:d63d0cc507440c59c222ee52b33593ce]
Artemether-lumefantrine; currently the first line treatment in Tanzania
Bio2RDF identifier
d63d0cc507440c59c222ee52b33593ce
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d63d0cc507440c59c222ee52b33593ce
measure [clinicaltrials_vocabulary:measure]
To determine the clinical effi ...... Tanzania and in western Kenya.
time frame [clinicaltrials_vocabulary:time-frame]
during 42 day follow-up
description
Artemether-lumefantrine; currently the first line treatment in Tanzania
identifier
clinicaltrials_resource:d63d0cc507440c59c222ee52b33593ce
title
To determine the clinical effi ...... Kenya. during 42 day follow-up
@en
type
label
To determine the clinical effi ...... d0cc507440c59c222ee52b33593ce]
@en